|
SMT201800527T1
(it)
|
2011-04-08 |
2018-11-09 |
Janssen Sciences Ireland Uc |
Derivati della pirimidina per il trattamento di infezioni virali
|
|
UA116083C2
(uk)
|
2011-11-09 |
2018-02-12 |
ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі |
Похідні пурину для лікування вірусних інфекцій
|
|
JP6283320B2
(ja)
|
2012-02-08 |
2018-02-21 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
ウイルス感染の治療のためのピペリジノ−ピリミジン誘導体
|
|
PT2872515T
(pt)
|
2012-07-13 |
2016-07-27 |
Janssen Sciences Ireland Uc |
Purinas macrocíclicas para o tratamento de infeções virais
|
|
SG11201502622VA
(en)
|
2012-10-10 |
2015-05-28 |
Janssen Sciences Ireland Uc |
PYRROLO[3,2-<i>D</i>]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES
|
|
NZ706226A
(en)
|
2012-11-16 |
2019-09-27 |
Janssen Sciences Ireland Uc |
Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
|
|
WO2014128189A1
(en)
|
2013-02-21 |
2014-08-28 |
Janssen R&D Ireland |
2-aminopyrimidine derivatives for the treatment of viral infections
|
|
JP6336036B2
(ja)
|
2013-03-29 |
2018-06-06 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
ウイルス感染治療のための大環状デアザプリノン
|
|
WO2014187932A1
(en)
|
2013-05-24 |
2014-11-27 |
Janssen R&D Ireland |
Pyridone derivatives for the treatment of viral infections and further diseases
|
|
DK3030563T3
(da)
|
2013-06-27 |
2017-11-20 |
Janssen Sciences Ireland Uc |
Pyrrolo-[3,2-d]-pyrimidin-derivater til behandling af virale infektioner og andre sygdomme
|
|
JP6401788B2
(ja)
|
2013-07-30 |
2018-10-10 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
ウイルス感染治療用チエノ［３，２−ｄ］ピリミジン誘導体
|
|
MD3097102T2
(ro)
|
2015-03-04 |
2018-02-28 |
Gilead Sciences Inc |
Compuşi de 4,6-diamino-pirido[3,2-D]pirimidină modulatori ai receptorilor de tip Toll
|
|
AU2016312508A1
(en)
|
2015-08-26 |
2018-02-15 |
Gilead Sciences, Inc. |
Deuterated toll-like receptor modulators
|
|
AU2016322763A1
(en)
|
2015-09-15 |
2018-04-19 |
Gilead Sciences, Inc. |
Modulators of toll-like recptors for the treatment of HIV
|
|
WO2017106346A2
(en)
|
2015-12-15 |
2017-06-22 |
Gilead Sciences, Inc. |
Human immunodeficiency virus neutralizing antibodies
|
|
CN118178444A
(zh)
|
2016-05-27 |
2024-06-14 |
吉利德科学公司 |
使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法
|
|
BR102017010009A2
(pt)
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
|
CN109476675B
(zh)
*
|
2016-07-01 |
2022-12-09 |
爱尔兰詹森科学公司 |
用于治疗病毒性感染的二氢吡喃并嘧啶衍生物
|
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
|
WO2018045150A1
(en)
|
2016-09-02 |
2018-03-08 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
|
CA3035346A1
(en)
*
|
2016-09-02 |
2018-03-08 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
|
DK3510033T3
(da)
*
|
2016-09-09 |
2022-02-28 |
Novartis Ag |
Forbindelser og sammensætninger som inhibitorer af endosomale toll-lignende receptorer
|
|
AU2017335205B2
(en)
|
2016-09-29 |
2021-11-04 |
Janssen Sciences Ireland Unlimited Company |
Pyrimidine prodrugs for the treatment of viral infections and further diseases
|
|
CN117402852A
(zh)
|
2016-10-14 |
2024-01-16 |
精密生物科学公司 |
对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶
|
|
AR110768A1
(es)
|
2017-01-31 |
2019-05-02 |
Gilead Sciences Inc |
Formas cristalinas de tenofovir alafenamida
|
|
JOP20180008A1
(ar)
|
2017-02-02 |
2019-01-30 |
Gilead Sciences Inc |
مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
|
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
|
TWI687415B
(zh)
|
2017-08-17 |
2020-03-11 |
美商基利科學股份有限公司 |
Hiv蛋白質膜抑制劑之固體形式
|
|
AR112412A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas de sal de colina de un inhibidor de la cápside del vih
|
|
WO2019040102A1
(en)
|
2017-08-22 |
2019-02-28 |
Gilead Sciences, Inc. |
THERAPEUTIC HETEROCYCLIC COMPOUNDS
|
|
WO2019057158A1
(zh)
*
|
2017-09-22 |
2019-03-28 |
江苏恒瑞医药股份有限公司 |
稠合杂芳基衍生物、其制备方法及其在医药上的应用
|
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
|
JP2021506827A
(ja)
|
2017-12-15 |
2021-02-22 |
シルバーバック セラピューティックス インコーポレイテッド |
肝炎の治療用の抗体コンストラクト−薬物コンジュゲート
|
|
KR102492187B1
(ko)
|
2017-12-20 |
2023-01-27 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드
|
|
US11203610B2
(en)
|
2017-12-20 |
2021-12-21 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
EP4227302A1
(en)
|
2018-02-13 |
2023-08-16 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
EP3752495B1
(en)
|
2018-02-15 |
2023-07-19 |
Gilead Sciences, Inc. |
Pyridine derivatives and their use for treating hiv infection
|
|
CN116854630A
(zh)
|
2018-02-16 |
2023-10-10 |
吉利德科学公司 |
用于制备可用于治疗逆转录病毒科病毒感染的治疗性化合物的方法和中间体
|
|
TWI772370B
(zh)
*
|
2018-02-26 |
2022-08-01 |
瑞士商諾華公司 |
作為胞內體類鐸（toll-like）受體抑制劑之化合物及組合物
|
|
KR102526964B1
(ko)
|
2018-02-26 |
2023-04-28 |
길리애드 사이언시즈, 인코포레이티드 |
Hbv 복제 억제제로서의 치환된 피롤리진 화합물
|
|
TW201945003A
(zh)
|
2018-03-01 |
2019-12-01 |
愛爾蘭商健生科學愛爾蘭無限公司 |
２，４－二胺基喹唑啉衍生物及其醫學用途
|
|
EP3774883A1
(en)
|
2018-04-05 |
2021-02-17 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TW201945388A
(zh)
|
2018-04-12 |
2019-12-01 |
美商精密生物科學公司 |
對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
|
|
CN112041311B
(zh)
|
2018-04-19 |
2023-10-03 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
|
TW202014193A
(zh)
|
2018-05-03 |
2020-04-16 |
捷克科學院有機化學與生物化學研究所 |
包含碳環核苷酸之2’3’－環二核苷酸
|
|
AR117573A1
(es)
|
2018-05-18 |
2021-08-18 |
Novartis Ag |
Formas cristalinas de un inhibidor tlr7 / tlr8
|
|
SG11202012043RA
(en)
|
2018-07-03 |
2021-01-28 |
Gilead Sciences Inc |
Antibodies that target hiv gp120 and methods of use
|
|
AU2019297428C1
(en)
|
2018-07-06 |
2023-03-23 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
|
EP3818052A1
(en)
|
2018-07-06 |
2021-05-12 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
|
CA3103286C
(en)
|
2018-07-13 |
2023-05-09 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
TWI842721B
(zh)
|
2018-07-16 |
2024-05-21 |
美商基利科學股份有限公司 |
用於治療hiv之蛋白殼抑制劑
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
WO2020056008A1
(en)
|
2018-09-12 |
2020-03-19 |
Silverback Therapeutics, Inc. |
Compositions for the treatment of disease with immune stimulatory conjugates
|
|
WO2020072656A1
(en)
|
2018-10-03 |
2020-04-09 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
|
CN112955435B
(zh)
|
2018-10-24 |
2024-09-06 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
|
DK3873903T3
(da)
|
2018-10-31 |
2024-04-02 |
Gilead Sciences Inc |
Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere
|
|
JP7273172B2
(ja)
|
2018-10-31 |
2023-05-12 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｐｋ１阻害活性を有する置換６－アザベンゾイミダゾール化合物
|
|
BR112021015577A8
(pt)
|
2019-02-08 |
2021-10-05 |
Research & Business Found Sungkyunkwan Univ |
Complexo-colesterol agonista do receptor toll-like 7/8, composição de nanopartícula, composição adjuvante, composição de vacina, composição para regular uma função imunológica, composição farmacêutica e uso do complexo
|
|
WO2020176510A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
|
WO2020176505A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
|
WO2020178769A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
|
AU2020231115B2
(en)
|
2019-03-07 |
2025-02-20 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
US11766447B2
(en)
|
2019-03-07 |
2023-09-26 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
CA3128961A1
(en)
|
2019-03-22 |
2020-10-01 |
Hang CHU |
Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
|
|
TWI751516B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI762925B
(zh)
|
2019-05-21 |
2022-05-01 |
美商基利科學股份有限公司 |
鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
|
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
|
US20220305115A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
|
JP2022536855A
(ja)
|
2019-06-19 |
2022-08-19 |
シルバーバック セラピューティックス インコーポレイテッド |
抗メソテリン抗体およびそのイムノコンジュゲート
|
|
CR20210687A
(es)
|
2019-06-25 |
2022-03-03 |
Gilead Sciences Inc |
PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
|
|
TWI879779B
(zh)
|
2019-06-28 |
2025-04-11 |
美商基利科學股份有限公司 |
類鐸受體調節劑化合物的製備方法
|
|
JP7454645B2
(ja)
|
2019-07-16 |
2024-03-22 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖワクチン並びにその作製方法及び使用方法
|
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
US20220296619A1
(en)
|
2019-08-19 |
2022-09-22 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
US11497808B2
(en)
|
2019-09-30 |
2022-11-15 |
Gilead Sciences, Inc. |
HBV vaccines and methods treating HBV
|
|
AU2020358726A1
(en)
|
2019-10-01 |
2022-04-07 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
|
EP4045083B1
(en)
|
2019-10-18 |
2024-01-10 |
Forty Seven, Inc. |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
|
JP2022552748A
(ja)
|
2019-10-31 |
2022-12-19 |
フォーティ セブン， インコーポレイテッド |
抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
CN114727999A
(zh)
|
2019-11-26 |
2022-07-08 |
吉利德科学公司 |
用于预防hiv的衣壳抑制剂
|
|
CN116057068A
(zh)
|
2019-12-06 |
2023-05-02 |
精密生物科学公司 |
对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶
|
|
PT4081305T
(pt)
|
2019-12-24 |
2024-12-04 |
Gilead Sciences Inc |
Compostos moduladores da diacilglicerol quinase
|
|
CA3169451A1
(en)
|
2020-02-14 |
2021-08-19 |
Jounce Therapeutics, Inc. |
Antibodies and fusion proteins that bind to ccr8 and uses thereof
|
|
JP7735291B2
(ja)
|
2020-02-21 |
2025-09-08 |
エーアールエス ファーマシューティカルズ、インコーポレイテッド |
ネクチン－４抗体コンジュゲートおよびその使用
|
|
WO2021177679A1
(ko)
|
2020-03-02 |
2021-09-10 |
성균관대학교산학협력단 |
병원균 외벽 성분 기반 생병원체 모방 나노 입자 및 그 제조 방법
|
|
WO2021188959A1
(en)
|
2020-03-20 |
2021-09-23 |
Gilead Sciences, Inc. |
Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
|
|
CN115698009B
(zh)
|
2020-05-01 |
2025-04-08 |
吉利德科学公司 |
抑制cd73的2,4-二氧代嘧啶化合物
|
|
TW202208355A
(zh)
|
2020-05-04 |
2022-03-01 |
美商安進公司 |
作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
|
|
PH12022552933A1
(en)
|
2020-05-04 |
2024-02-12 |
Amgen Inc |
Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
|
|
WO2021236944A1
(en)
|
2020-05-21 |
2021-11-25 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising bictegravir
|
|
CA3181690A1
(en)
|
2020-06-25 |
2021-12-30 |
Chienhung CHOU |
Capsid inhibitors for the treatment of hiv
|
|
AU2021300362A1
(en)
|
2020-07-01 |
2023-02-23 |
ARS Pharmaceuticals, Inc. |
Anti-ASGR1 antibody conjugates and uses thereof
|
|
JP7690222B2
(ja)
|
2020-08-04 |
2025-06-10 |
プロジェニア インコーポレイテッド |
動力学的制御が可能なアジュバントを含むｍＲＮＡワクチン
|
|
EP4194008A4
(en)
|
2020-08-04 |
2025-01-08 |
Progeneer Inc. |
Kinetically acting adjuvant ensemble
|
|
WO2022031057A1
(ko)
|
2020-08-04 |
2022-02-10 |
성균관대학교산학협력단 |
활성화 부위가 일시적으로 비활성화된 톨-유사 수용체 7 또는 8 작용자와 기능성 약물의 결합체 및 그 용도
|
|
US20230303599A1
(en)
|
2020-08-07 |
2023-09-28 |
Gilead Sciences, Inc. |
Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
|
|
TW202406932A
(zh)
|
2020-10-22 |
2024-02-16 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
CA3195799A1
(en)
|
2020-11-11 |
2022-05-19 |
Stephen R. Martin |
Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies
|
|
US20240209080A1
(en)
|
2021-04-10 |
2024-06-27 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
JP7742892B2
(ja)
|
2021-04-23 |
2025-09-22 |
ジェンマブ エー／エス |
抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法
|
|
WO2022241134A1
(en)
|
2021-05-13 |
2022-11-17 |
Gilead Sciences, Inc. |
COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
|
|
WO2022245671A1
(en)
|
2021-05-18 |
2022-11-24 |
Gilead Sciences, Inc. |
Methods of using flt3l-fc fusion proteins
|
|
JP7651018B2
(ja)
|
2021-06-23 |
2025-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
JP7654118B2
(ja)
|
2021-06-23 |
2025-03-31 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
EP4359413A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271677A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
TWI857377B
(zh)
|
2021-10-28 |
2024-10-01 |
美商基利科學股份有限公司 |
嗒-3(2h)-酮衍生物
|
|
EP4422756A1
(en)
|
2021-10-29 |
2024-09-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
TW202342447A
(zh)
|
2021-12-03 |
2023-11-01 |
美商基利科學股份有限公司 |
用於ｈｉｖ病毒感染之治療性化合物
|
|
EP4440700A1
(en)
|
2021-12-03 |
2024-10-09 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv virus infection
|
|
EP4440702B1
(en)
|
2021-12-03 |
2025-05-21 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv virus infection
|
|
WO2023104165A1
(zh)
*
|
2021-12-08 |
2023-06-15 |
上海维申医药有限公司 |
作为TLR7/8激动剂的吡啶[4,3-d]嘧啶类化合物
|
|
US20230203202A1
(en)
|
2021-12-08 |
2023-06-29 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
US20230220106A1
(en)
|
2021-12-08 |
2023-07-13 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
JP2024546851A
(ja)
|
2021-12-22 |
2024-12-26 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
|
|
EP4452415A1
(en)
|
2021-12-22 |
2024-10-30 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
PE20242225A1
(es)
|
2022-03-17 |
2024-11-19 |
Gilead Sciences Inc |
Degradadores de dedos de zinc de la familia ikaros y usos de estos
|
|
US20230355796A1
(en)
|
2022-03-24 |
2023-11-09 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
TWI856796B
(zh)
|
2022-04-06 |
2024-09-21 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
|
IL316058A
(en)
|
2022-04-21 |
2024-11-01 |
Gilead Sciences Inc |
Compounds modulate KRAS G12D
|
|
EP4547657A1
(en)
|
2022-07-01 |
2025-05-07 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
US20240034724A1
(en)
|
2022-07-01 |
2024-02-01 |
Gilead Sciences, Inc. |
Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
|
|
AU2023307100A1
(en)
|
2022-07-12 |
2025-01-02 |
Gilead Sciences, Inc. |
Hiv immunogenic polypeptides and vaccines and uses thereof
|
|
WO2024044477A1
(en)
|
2022-08-26 |
2024-02-29 |
Gilead Sciences, Inc. |
Dosing and scheduling regimen for broadly neutralizing antibodies
|
|
US20240091351A1
(en)
|
2022-09-21 |
2024-03-21 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
US20240226130A1
(en)
|
2022-10-04 |
2024-07-11 |
Gilead Sciences, Inc. |
4'-thionucleoside analogues and their pharmaceutical use
|
|
KR20250122479A
(ko)
|
2022-12-22 |
2025-08-13 |
길리애드 사이언시즈, 인코포레이티드 |
Prmt5 억제제 및 이의 용도
|
|
WO2024215754A1
(en)
|
2023-04-11 |
2024-10-17 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2024220624A1
(en)
|
2023-04-19 |
2024-10-24 |
Gilead Sciences, Inc. |
Dosing regimen of capsid inhibitor
|
|
WO2024220917A1
(en)
|
2023-04-21 |
2024-10-24 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2024249592A1
(en)
|
2023-05-31 |
2024-12-05 |
Gilead Sciences, Inc. |
Quinazolinyl-indazole derivatives as therapeutic compounds for hiv
|
|
WO2024249573A1
(en)
|
2023-05-31 |
2024-12-05 |
Gilead Sciences, Inc. |
Solid forms of compounds useful in the treatment of hiv
|
|
US20250042922A1
(en)
|
2023-06-30 |
2025-02-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
US20250100998A1
(en)
|
2023-07-26 |
2025-03-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
US20250066328A1
(en)
|
2023-07-26 |
2025-02-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025029247A1
(en)
|
2023-07-28 |
2025-02-06 |
Gilead Sciences, Inc. |
Weekly regimen of lenacapavir for the treatment and prevention of hiv
|
|
WO2025042394A1
(en)
|
2023-08-23 |
2025-02-27 |
Gilead Sciences, Inc. |
Dosing regimen of hiv capsid inhibitor
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025054530A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
WO2025072406A1
(en)
|
2023-09-26 |
2025-04-03 |
Profoundbio Us Co. |
Ptk7 binding agents, conjugates thereof and methods of using the same
|
|
US20250120989A1
(en)
|
2023-10-11 |
2025-04-17 |
Gilead Sciences, Inc. |
Bridged tricyclic carbamoylpyridone compounds and uses thereof
|
|
US20250127801A1
(en)
|
2023-10-11 |
2025-04-24 |
Gilead Sciences, Inc. |
Bridged tricyclic carbamoylpyridone compounds and uses thereof
|
|
WO2025080863A1
(en)
|
2023-10-11 |
2025-04-17 |
Gilead Sciences, Inc. |
Bridged tricyclic carbamoylpyridone compounds and uses thereof
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20250230168A1
(en)
|
2023-12-22 |
2025-07-17 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025137245A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Solid forms of hiv integrase inhibitors
|
|
US20250296992A1
(en)
|
2024-01-10 |
2025-09-25 |
Genmab A/S |
Slitrk6 binding agents, conjugates thereof and methods of using the same
|
|
WO2025181219A1
(en)
|
2024-02-29 |
2025-09-04 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
WO2025184609A1
(en)
|
2024-03-01 |
2025-09-04 |
Gilead Sciences, Inc. |
Antiviral compounds
|
|
WO2025184447A1
(en)
|
2024-03-01 |
2025-09-04 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising hiv integrase inhibitors
|
|
WO2025184452A1
(en)
|
2024-03-01 |
2025-09-04 |
Gilead Sciences, Inc. |
Solid forms of hiv integrase inhibitors
|